WASHINGTON, March 30- A new type of heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said.
LONDON, March 30- GlaxoSmithKline plans to make new investments in additional factories and drug research in Africa, its chief executive said on Sunday, as the pharmaceuticals group broadens its bet on promising emerging markets.
WASHINGTON, March 30- An experimental heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said Sunday.
LONDON, March 28- Buyout firms are finding it harder to take part in mergers and acquisitions as the lure of stronger equity markets persuades more funds seeking to exit assets to try their luck with a public share sale or turn to cash-rich corporate buyers.
LONDON, March 27- Britain's healthcare agency NICE, which determines the use of treatments in the state-run health service, may be more likely to say' yes' to new drugs under proposals that enable it to take a broader view of the value they offer.
*All retail supplies recalled in U.S. and Puerto Rico. LONDON, March 27- GlaxoSmithKline is recalling all supplies of its non-prescription weight-loss drug Alli in the United States and Puerto Rico after customers reported finding other pills and tablets in some bottles.
Some of the names on the move ahead of the open.
March 26- Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.
March 26- Some bottles of Alli, GlaxoSmithKline Plc's weight-loss drug sold over the counter in the United States, have been tampered with, and the Food and Drug Administration was investigating, the company said on Wednesday.
March 26- GlaxoSmithKline Plc said some bottles of its weight-loss drug Alli bought in the United States had been tampered with and that the U.S. Food and Drug Administration was investigating. Consumers reported that some bottles bought in stores in seven states contained products other than the drug, the company said on Wednesday.
*Sanofi hopes to deliver first doses in late 2015. *Sanofi has spent over 1.3 bln euros on project.
European stock markets trimmed last week's gains to close lower on Monday, off the back of weak Chinese data and tensions in Ukraine.
*China's lower-than-expected PMI weighs on sentiment. PARIS, March 24- European stocks slipped in early trade on Monday, trimming last week's lofty gains, as data showing China's manufacturing activity contracted in the first quarter of 2014 revived worries over the outlook for global growth.
Wall Street opened lower but reversed course after the Philadelphia Federal Reserve Bank said its business activity index rose far more than expected in March, rebounding after a contraction in February.
*Ukraine in view as Russia seizes naval bases. *Lennar Corp, Jabil Circuit both rise after results. NEW YORK, March 20- U.S. stock index futures pointed to a modestly lower open on Thursday as investors continued to digest comments from Federal Reserve Chair Janet Yellen, who raised the specter of an earlier-than-expected rate hike.
*Novartis reviewing fate of animal health, vaccines and OTC units. BASEL, Switzerland, March 20- Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be a "brutal" new era in healthcare spending.
*Ukraine in view as Russia seizes naval bases. NEW YORK, March 20- U.S. stock index futures were lower on Thursday as investors continued to digest recent comments from Federal Reserve Chair Janet Yellen, who raised the specter of an earlier-than-expected rate hike.
*MAGE-A3 fails to hit goal in Phase III lung cancer trial. March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British company said it still hoped to identify a sub-group of patients in which it would work.
March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British group said it still hoped to find a sub-group of patients in which it would work.
*Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.